Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 3
2001 3
2002 2
2003 1
2004 2
2005 3
2007 1
2008 2
2010 1
2011 1
2012 2
2014 2
2015 2
2018 2
2019 2
2020 3
2021 3
2022 5
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. N Engl J Med. 2020. PMID: 32101663 Clinical Trial.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. N Engl J Med. 2022. PMID: 35139274 Clinical Trial.
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Tutt A, et al. Among authors: harper wynne c. Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30. Nat Med. 2018. PMID: 29713086 Free PMC article. Clinical Trial.
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.
Turner NC, Swift C, Jenkins B, Kilburn L, Coakley M, Beaney M, Fox L, Goddard K, Garcia-Murillas I, Proszek P, Hall P, Harper-Wynne C, Hickish T, Kernaghan S, Macpherson IR, Okines AFC, Palmieri C, Perry S, Randle K, Snowdon C, Stobart H, Wardley AM, Wheatley D, Waters S, Winter MC, Hubank M, Allen SD, Bliss JM; c-TRAK TN investigators. Turner NC, et al. Among authors: harper wynne c. Ann Oncol. 2023 Feb;34(2):200-211. doi: 10.1016/j.annonc.2022.11.005. Epub 2022 Nov 22. Ann Oncol. 2023. PMID: 36423745 Free article. Clinical Trial.
Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer.
Coakley M, Villacampa G, Sritharan P, Swift C, Dunne K, Kilburn L, Goddard K, Pipinikas C, Rojas P, Emmett W, Hall P, Harper-Wynne C, Hickish T, Macpherson I, Okines A, Wardley A, Wheatley D, Waters S, Palmieri C, Winter M, Cutts RJ, Garcia-Murillas I, Bliss J, Turner NC. Coakley M, et al. Among authors: harper wynne c. Clin Cancer Res. 2024 Feb 16;30(4):895-903. doi: 10.1158/1078-0432.CCR-23-2326. Clin Cancer Res. 2024. PMID: 38078899 Free PMC article.
Breast cancer.
Ring A, Harper-Wynne C, Smith I. Ring A, et al. Among authors: harper wynne c. Cancer Chemother Biol Response Modif. 2005;22:545-61. Cancer Chemother Biol Response Modif. 2005. PMID: 16110628 Review. No abstract available.
A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP).
Starkey T, Ionescu MC, Tilby M, Little M, Burke E, Fittall MW, Khan S, Liu JKH, Platt JR, Mew R, Tripathy AR, Watts I, Williams ST, Appanna N, Al-Hajji Y, Barnard M, Benny L, Burnett A, Bytyci J, Cattell EL, Cheng V, Clark JJ, Eastlake L, Gerrand K, Ghafoor Q, Grumett S, Harper-Wynne C, Kahn R, Lee AJX, Lomas O, Lydon A, Mckenzie H; NCRI Consumer Forum; Panneerselvam H, Pascoe JS, Patel G, Patel V, Potter VA, Randle A, Rigg AS, Robinson TM, Roylance R, Roques TW, Rozmanowski S, Roux RL, Shah K, Sheehan R, Sintler M, Swarup S, Taylor H, Tillett T, Tuthill M, Williams S, Ying Y, Beggs A, Iveson T, Lee SM, Middleton G, Middleton M, Protheroe A, Fowler T, Johnson P, Lee LYW. Starkey T, et al. Among authors: harper wynne c. Sci Rep. 2023 Jul 25;13(1):11327. doi: 10.1038/s41598-023-36990-9. Sci Rep. 2023. PMID: 37491478 Free PMC article.
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program.
Palmieri C, Musson A, Harper-Wynne C, Wheatley D, Bertelli G, Macpherson IR, Nathan M, McDowall E, Bhojwani A, Verrill M, Eva J, Doody C, Chowdhury R. Palmieri C, et al. Among authors: harper wynne c. Br J Cancer. 2023 Sep;129(5):852-860. doi: 10.1038/s41416-023-02352-5. Epub 2023 Jul 19. Br J Cancer. 2023. PMID: 37468569 Free PMC article. Clinical Trial.
Rechallenging with anthracyclines and taxanes in metastatic breast cancer.
Palmieri C, Krell J, James CR, Harper-Wynne C, Misra V, Cleator S, Miles D. Palmieri C, et al. Among authors: harper wynne c. Nat Rev Clin Oncol. 2010 Oct;7(10):561-74. doi: 10.1038/nrclinonc.2010.122. Epub 2010 Aug 31. Nat Rev Clin Oncol. 2010. PMID: 20808300 Review.
Aromatase inhibitors and their use in the sequential setting.
Coombes RC, Harper-Wynne C, Dowsett M. Coombes RC, et al. Among authors: harper wynne c. Endocr Relat Cancer. 1999 Jun;6(2):259-63. doi: 10.1677/erc.0.0060259. Endocr Relat Cancer. 1999. PMID: 10731118 Review.
41 results